Treatments for negative symptoms

What are negative symptoms? 

Negative symptoms are referring to an absence of normal functions. This may include (but is not limited to) blunted affect, which is a scarcity of facial expressions of emotion, reduced frequency and range of gestures and voice modulation, and restricted eye contact; alogia (poverty of speech); asociality (reduced social interaction); avolition (reduced motivation and often poor hygiene) and anhedonia, which is reduced experience of pleasure.

What is the evidence on treatments for negative symptoms?

Moderate quality evidence finds some benefit for improving negative symptoms from second-generation, but not first-generation antipsychotics compared to placebo. Moderate to low quality evidence finds some benefit of antipsychotics plus psychological interventions compared to antipsychotics alone. For individual antipsychotics, amisulpride provided more benefit than placebo; cariprazine, olanzapine and quetiapine provided more benefit than risperidone; olanzapine provided more benefit than haloperidol. Fluphenazine-treated patients received more antiparkinson medication than those on amisulpride or risperidone, risperidone-treated patients received more antiparkinson medication than those on quetiapine, and risperidone produced more extra-pyramidal symptoms than olanzapine.

For other agents, moderate quality evidence finds a small benefit for negative symptoms with adjunctive antidepressants, particularly SNRIs and SSRIs, and with adjunctive glutamatergic agents. Antidepressants were associated with more abdominal pain, constipation, dizziness, and dry mouth than placebo. Moderate to high quality evidence finds a medium-sized improvement in negative symptoms with anti-dementia medications compared to placebo, particularly galantamine, rivastigmine and memantine. There were no differences in adverse events between anti-dementia medications and placebo. Moderate to low quality evidence finds there may also be benefits of other adjunctive agents including aspirin, atomoxetine, celecoxib, cerebrolysin, amotidine, folate, granisetron, insulin, latrepirdine, mazindol, mianserin, mirtazapine, methotrimeprazine, oxytocin, pramipexole, reboxetine, selegiline, sildenafil, sodium benzoate, tropisetron, viloxazine, and vitamin B12.

October 2019

Last updated at: 3:01 am, 30th October 2019
To view documentation related to this topic download the files below
Fact Sheet Technical Commentary

NeuRA Libraries

Title Colour Legend:
Green - Topic summary is available.
Orange - Topic summary is being compiled.
Red - Topic summary has no current systematic review available.